BMS/AbbVie's combo falls short in untreated multiple myeloma...

Adding Bristol-Myers Squibb/AbbVie's Empliciti to Revlimid, developed by BMS' recently acquired Celgene unit, does not improve survival in untreated multiple myeloma, a study has shown.

Boehringer bags CHMP backing for Ofev in rare lung disease

NICE backs Celgene’s Revlimid for chemo-free lymphoma therap...

FDA to fast-track review of BMS' CAR-T, ahead of shareholder...

Speculators who bought into a risky three-drug bet are still on track for a payout following Celgene's merger with Bristol-Myers Squibb, after the FDA agreed to fast-track its review of a n

Boosted by Celgene's cash, BMS bounces back after mega-merge...

Bristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year results from the previously struggling pharma.

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma